MUC1-based recombinant Bacillus Calmette–Guerin vaccines as candidates for breast cancer immunotherapy

Bibliography

• Shumway NM, Ibrahim N, Ponniah S, Therapeutic breast cancer vaccines: a new strategy for early-stage disease. BioDrugs 2009;23:277-87
   PubMed Web of Science ®Google Scholar
• Huber CH, Wolfel T. Immunotherapy of cancer: from vision to standard clinical practice. J Cancer Res Clin Oncol 2004;130:367-74
   PubMed Web of Science ®Google Scholar
• Emens LA, Reilly RT, Jafee EM. Augmenting the potency of breast cancer vaccines: combined modality immunotharapy. Breast Dis 2009;3:13-24
   Google Scholar
• Singh R, Bandyopadhyay D. MUC1: a target molecule for cancer therapy. Cancer Biol Ther 2007;6:481-6
   PubMed Web of Science ®Google Scholar
• Taylor-Papadimitriou J, Burchell J, Miles DW, MUC1 and cancer. Biochim Biophys Acta 1999;1455:301-13
   PubMed Web of Science ®Google Scholar
• Saito H, Dubsky P, Dantin C, Cross-priming of cyclin B1, MUC-1 and survivin-specific CD8+ T cells by dendritic cells loaded with killed allogeneic breast cancer cells. Breast Cancer Res 2006;8(6):R65
   PubMedGoogle Scholar
• Baldus SE, Engelmann K, Hanisch FG. MUC1 and the MUCs: a family of human mucins with impact in cancer biology. Crit Rev Clin Lab Sci 2004;41:189-231
   PubMed Web of Science ®Google Scholar
• Zhang S, Graeber LA, Helling F, Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice. Cancer Res 1996;56:3315-19
   PubMed Web of Science ®Google Scholar
• Hanisch FG. Design of a MUC1-based cancer vaccine. Biochem Soc Trans 2005;33:705-8
   PubMed Web of Science ®Google Scholar
• Huo Y, Li B, Zhang Y, Pre-clinical safety evaluation of heat shock protein 65-MUC1 peptide fusion protein. Regul Toxicol Pharmacol 2007;49:63-74
   Google Scholar
• Mushenkova N, Moiseeva E, Chaadaeva A, Antitumor effect of double immunization of mice with mucin 1 and its coding DNA. Anticancer Res 2005;25:3893-8
   PubMed Web of Science ®Google Scholar
• Yang E, Hu XF, Xing PX. Advances of MUC1 as a target for breast cancer immunotherapy. Histol Histopathol 2007;22:905-22
   PubMed Web of Science ®Google Scholar
• Koido S, Kashiwaba M, Chen D, Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol 2000;165:5713-19
   PubMed Web of Science ®Google Scholar
• Rosenblatt J, Kufe D, Avigan D. Dendritic cell fusion vaccines for cancer immunotherapy. Expert Opin Biol Ther 2005;5:703-15
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Koido S, Chen D, Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin Immunol 2001;101:192-200
   PubMed Web of Science ®Google Scholar
• Graham RA, Burchell JM, Beverley P, Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Int J Cancer 1996;65:664-70
   PubMed Web of Science ®Google Scholar
• Chu Y, Xia M, Lin Y, Th2-dominated antitumor immunity induced by DNA immunization with the genes coding for a basal core peptide PDTRP and GM-CSF. Cancer Gene Ther 2006;13:510-19
   PubMed Web of Science ®Google Scholar
• Johnen H, Kulbe H, Pecher G. Long-term tumor growth suppression in mice immunized with naked DNA of the human tumor antigen mucin (MUC1). Cancer Immunol Immunother 2001;50:356-60
   PubMed Web of Science ®Google Scholar
• Barletta RG, Snapper B, Cirillo JD, Recombinant BCG as a candidate oral vaccine vector. Res Microbiol 1990;141:931-39
   PubMed Web of Science ®Google Scholar
• Stover CK, de la Cruz VF, Fuerst TR, New use of BCG for recombinant vaccines. Nature 1991;351:456-60
   PubMed Web of Science ®Google Scholar
• Hanson MS, Bansal GP, Langermann S, Efficacy and safety of live recombinant BCG vaccines. Dev Biol Stand 1995;84:229-36
   PubMedGoogle Scholar
• Chambers MA, Williams A, Gavier-Widen D, Identification of a Mycobacterium bovis BCG auxotrophic mutant that protects guinea pigs against M. bovis and hematogenous spread of Mycobacterium tuberculosis without sensitization to tuberculin. Infect Immun 2000;68:7094-9
   PubMed Web of Science ®Google Scholar
• Hernà ndez-Pando R, Castañòn M, Espitia C, Recombinant BCG vaccine candidates. Curr Mol Med 2007;7:365-72
   PubMed Web of Science ®Google Scholar
• Tang CK, Apostolopoulos V. Strategies used for MUC1 immunotherapy: preclinical studies. Expert Rev Vaccines 2008;7:951-62
   PubMed Web of Science ®Google Scholar
• Feuerer M, Beckhove P, Bai L, Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 2001;7:452-8
   PubMed Web of Science ®Google Scholar
• Brossart P, Heinrich KS, Stuhler G, Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 1999;93:4309-17
   PubMed Web of Science ®Google Scholar
• Correa I, Plunkett T, Coleman J, Responses of human T cells to peptides flanking the tandem repeat and overlapping the signal sequence of MUC1. Int J Cancer 2005;115:760-8
   PubMed Web of Science ®Google Scholar
• Tarp MA, Clausen H. Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta 2008;1780:546-63
   PubMed Web of Science ®Google Scholar
• Stepensky D, Tzehoval E, Vadai E, O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma. Clin Exp Immunol 2006;143:139-49
   PubMed Web of Science ®Google Scholar
• Dziadek S, Griesinger C, Kunz H, Synthesis and structural model of an ?(2,6)-sialyl-T glycosylated MUC1 eicosapeptide under physiological conditions. Chemistry 2006;12:4981-93
   PubMed Web of Science ®Google Scholar
• Westerlind U, Schröder H, Alexandra Hobel, Tumor-associated MUC1 tandem-repeat glycopeptide microarrays to evaluate serum- and monoclonal-antibody specificity. Angew Chem Int Ed 2009;48:8263-7
   PubMed Web of Science ®Google Scholar
• Taylor PJ, Burchell JM, Plunkett T, MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 2002;7:209-21
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, McKenzie IF. Cellular mucins: targets for immunotherapy. Crit Rev Immunol 1994;14:293-309
   Google Scholar
• Domschke C, Schuetz F, Ge Y, Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res 2009;69:8420-8
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Hu XF, Pouniotis DS, MUC1: a molecule of many talents. Curr Trends Immunol 2003;12:629-39
   Google Scholar
• Apostolopoulos V, McKenzie IF, Pietersz GA. Breast cancer immunotherapy: current status and future prospects. Immunol Cell Biol 1996;74:457-64
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Pietersz GA, McKenzie IF. MUC1 and breast cancer. Curr Opin Mol Ther 1999;1:98-103
   PubMed Web of Science ®Google Scholar
• Kaiser A, Gaidzik N, Westerlind U, A synthetic vaccine consisting of a tumor-associated sialyl-TN-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response. Angew Chem Int Ed Engl 2009;48:7551-5
   PubMed Web of Science ®Google Scholar
• Kotera Y, Fontenot JD, Pecher G, Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 1994;54:2856-60
   PubMed Web of Science ®Google Scholar
• Tarp MA, Sorensen AL, Mandel U, Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology 2007;17:197-209
   PubMed Web of Science ®Google Scholar
• Chen D, Xia J, Tanaka Y, Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology 2003;109:300-7
   PubMed Web of Science ®Google Scholar
• Kohlgraf KG, Gawron AJ, Higashi M, Tumor-specific immunity in MUC1. Tg mice induced by immunization with peptide vaccines from the cytoplasmatic tail of CD227 (MUC1). Cancer Immunol Immunother 2004;53:1068-84
   PubMed Web of Science ®Google Scholar
• Finn OJ, Jerome KR, Henderson RA, MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 1995;145:61-89
   PubMed Web of Science ®Google Scholar
• Acres B, Limacher JM. MUC1 as a target antigen for cancer immunotherapy. Expert Rev Vaccines 2005;4:493-502
   PubMed Web of Science ®Google Scholar
• Vlad AM, Kettel JC, Alajez NM, MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 2004;82:249-93
   PubMed Web of Science ®Google Scholar
• Soares MM, Mehta V, Finn OJ. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumorspecific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J Immunol 2001;166:6555-63
   PubMed Web of Science ®Google Scholar
• Goydos JS, Elder E, Whiteside TL, A Phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 1996;63:298-304
   PubMed Web of Science ®Google Scholar
• Reddish MA, MacLean GD, Koganty RR, Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int J Cancer 1998;76:817-23
   PubMed Web of Science ®Google Scholar
• Adluri S, Gilewski T, Zhang S, Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21. Br J Cancer 1999;79:1806-12
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Pietersz GA, McKenzie IFC. Cell-mediated immune response to MUC-1 fusion protein coupled to mannan. Vaccine 1996;14:930-8
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Loveland BE, Pietersz GA, CTL in mice immunized with human mucin 1 are MHC-restricted. J Immunol 1995;155:5089-94
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Pietersz GA, McKenzia IFC. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune response. Proc Natl Acad Sci 1995;92:10128-32
   PubMed Web of Science ®Google Scholar
• Karanikas V, Hwang LA, Pearson J. Antibody and T-cell responses of patients with adenocarcinoma immunized with mann-MUC-1 fusion protein. J Clin Invest 1997;100:2783-90
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Pietersz GA, Tsibanis A, Pilot Phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan–MUC1 [ISRCTN71711835]. Breast Cancer Res 2006;8:R27
   PubMed Web of Science ®Google Scholar
• Musselli C, Ragupathi G, Gilewski T, Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Int J Cancer 2002;97:660-7
   PubMed Web of Science ®Google Scholar
• Gilewski T, Adluri S, Ragupathi G. Vaccination of high risk breast cancer patients with MUC-1 keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 2000;6:1693-701
   PubMed Web of Science ®Google Scholar
• Mukherjee P, Madsen CS, Ginardi AR, Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer. J Immunother 2003;26:47-62
   PubMed Web of Science ®Google Scholar
• Ryan SO, Vlad AM, Islam K, Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice. Biol Chem 2009;390:611-18
   PubMed Web of Science ®Google Scholar
• Plunkett T, Graham R, Correa I, Protection against MUC1 expressing mouse tumours by intra-muscular injection of MUC1 cDNA requires functional CD8+ and CD4+ T cells but does not require the MUC1 tandem repeat domain. Int J Cancer 2004;109:691-7
   PubMed Web of Science ®Google Scholar
• Snyder LA, Goletz TJ, Gunn GR, A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice. Vaccine 2006;24:3340-52
   PubMed Web of Science ®Google Scholar
• Jeon YH, Choi Y, Kim HJ, Human sodium iodide symporter gene adjunctive radiotherapy to enhance the preventive effect of hMUC1 DNA vaccine. Int J Cancer 2007;121:1593-9
   PubMed Web of Science ®Google Scholar
• Scholl SM, Balloul JM, Le GG, Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother 2000;23:570-80
   PubMed Web of Science ®Google Scholar
• Liu M, Acres B, Balloul JM, Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 2004;101(Suppl 2):14567-71
   PubMedGoogle Scholar
• Zhang S, Zhang H, Shi H, Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats. Hum Immunol 2008;69:250-8
   PubMed Web of Science ®Google Scholar
• Tang CK, Sheng KC, Pouniotis D, Oxidized and reduced mannan mediated MUC1 DNA immunization induce effective anti-tumor responses. Vaccine 2008;26:3827-34
   PubMed Web of Science ®Google Scholar
• Gong J, Avigan D, Chen D, Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA 1998;97:2715-18
   Web of Science ®Google Scholar
• Gong J, Apostolopoulos V, Chen D, Selection and characterization of MUC1–specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic–carcinoma fusion cells. Immunology 2000;101:316-24
   PubMed Web of Science ®Google Scholar
• Gong J, Chen D, Kashiwaba M, Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997;3:558-61
   PubMed Web of Science ®Google Scholar
• Gong J, Chen D, Kashiwaba M, Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci USA 1998;95:6279-83
   PubMed Web of Science ®Google Scholar
• Maruyama K, Akiyama Y, Nara-Ashizawa N, Adenovirus-mediated MUC1 gene transduction into human blood-derived dendritic cells. J Immunother 2001;24:345-53
   PubMed Web of Science ®Google Scholar
• Pecher G, Haring A, Kaiser L, Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a Phase I/II clinical trial. Cancer Immunol Immunother 2002;51:669-73
   PubMed Web of Science ®Google Scholar
• Sheng KC, Pietersz GA, Wright MD, Dendritic cells: activation and maturation – applications for cancer immunotherapy. Curr Med Chem 2005;12:1783-800
   PubMed Web of Science ®Google Scholar
• Kontani K, Taguchi O, Ozaki Y, Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int J Mol Med 2003;12:493-502
   PubMed Web of Science ®Google Scholar
• Yang H, Cho NH, Seong SY. The Tat-conjugated N-terminal region of mucin antigen 1 (MUC1) induces protective immunity against MUC1-expressing tumours. Clin Exp Immunol 2009;158:174-85
   PubMed Web of Science ®Google Scholar
• Brossart P, Wirths S, Stuhler G, Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000;96:3102-8
   PubMed Web of Science ®Google Scholar
• Loveland BE, Zhao A, White S, Mannan-MUC1-pulsed dendritic cell immunotherapy: a Phase I trial in patients with adenocarcinoma. Clin Cancer Res 2006;12:869-77
   PubMed Web of Science ®Google Scholar
• Osada T, Clay TM, Woo CY, Dendritic cell-based immunotherapy. Int Rev Immunol 2006;25:377-413
   PubMed Web of Science ®Google Scholar
• Tatsumi T, Storkus WJ. Dendritic cell-based vaccines and therapies for cancer. Expert Opin Biol Ther 2002;2:919-28
   PubMed Web of Science ®Google Scholar
• Fay JW, Palucka AK, Paczesny S, Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cells. Cancer Immunol Immunother 2006;55:1209-18
   PubMed Web of Science ®Google Scholar
• Avichezer D, Springer GF, Schechter B, Immunoreactivities of polyclonal and monoclonal anti-T and anti-Tn antibodies with human carcinoma cells, grown in vitro and in a xenograft model. Int J Cancer 1997;72:119-27
   PubMed Web of Science ®Google Scholar
• Springer GF. Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med 1997;75:594-602
   PubMed Web of Science ®Google Scholar
• Longenecker BM, Reddish M, Koganty R, Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant. Ann NY Acad Sci 1993;690:276-91
   PubMed Web of Science ®Google Scholar
• Miles DW, Towlson KE, Graham R, A randomised Phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer 1996;74:1292-6
   PubMed Web of Science ®Google Scholar
• Sandmaier BM, Oparin DV, Holmberg LA, Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn- KLH cancer vaccine. J Immunother 1999;22:54-66
   PubMed Web of Science ®Google Scholar
• Holmberg LA, Oparin DV, Gooley T, The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope). Clin Breast Cancer 2003;3(Suppl 4):S144-51
   PubMedGoogle Scholar
• Acres B, Apostolopoulos V, Balloul JM, MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol Immunother 2000;48:588-94
   PubMed Web of Science ®Google Scholar
• Rochlitz C, Figlin R, Squiban P, Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 2003;5:690-9
   PubMed Web of Science ®Google Scholar
• Acres B, Bonnefoy JY. Clinical development of MVA-based therapeutic cancer vaccines. Expert Rev Vaccines 2008;7:889-93
   PubMed Web of Science ®Google Scholar
• Harrop R, Carroll MW. Viral vectors for cancer immunotherapy. Front Biosci 2006;11:804-17
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Tsang KY, Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 2008;14:3060-9
   PubMed Web of Science ®Google Scholar
• Acres B. Cancer immunotherapy: Phase II clinical studies with TG4010 (MVA-MUC1-IL2). J BUON 2007;12(Suppl 1):S71-5
   PubMedGoogle Scholar
• Singh R, Samant U, Hyland S, Target specific cytotoxic activity of recombinant immunotoxin scFv (MUC1)– ETA on breast carcinoma cells and primary breast tumors. Mol Cancer Ther 2007;6:562-9
   PubMed Web of Science ®Google Scholar
• Danielczyk A, Stahn R, Faulstich D, PankoMab: a potent new generation anti-tumour MUC1 antibody. Cancer Immunol Immunother 2006;55:1337-47
   PubMed Web of Science ®Google Scholar
• Brennan MJ, Morris SL, Sizemore CF. Tuberculosis vaccine development: research, regulatory and clinical strategies. Expert Opin Biol Ther 2004;4:1493-504
   PubMed Web of Science ®Google Scholar
• Ohara N and Yamada T. Recombinant BCG vaccines. Vaccine 2001;19:4089-98
   PubMed Web of Science ®Google Scholar
• Shi C, Yuan S, Zhang H, Cell-mediated immune responses and protective efficacy against infection with Mycobacterium tuberculosis induced by Hsp65 and hIL-2 fusion protein in mice. Scand J Immunol 2009;69(2):140-9
   PubMed Web of Science ®Google Scholar
• Colditz GA, Brewer TF, Berkey CS, Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994;271:698-702
   PubMed Web of Science ®Google Scholar
• Jacobs WR Jr, Tuckman M, Bloom BR. Introduction of foreign DNA into mycobacteria using a shuttle phasmid. Nature 1987;327(6122):532-5
   PubMed Web of Science ®Google Scholar
• Dai W, Huang H, Yuan Y, Novel vaccination strategies based on recombinant Mycobacterium bovis BCG. Int J Med Microbiol 2003;292:441-51
   PubMed Web of Science ®Google Scholar
• Liu W, O'Donnell MA, Chen X, Recombinant bacillus Calmette–Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro. Cancer Immunol Immunother 2009;58:1647-55
   PubMed Web of Science ®Google Scholar
• Chade DC, Borra RC, Nascimento IP, Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model. J Exp Clin Cancer Res 2008;27:78
   PubMed Web of Science ®Google Scholar
• Dennehy M, Williamson AL. Factors influencing the immune response to foreign antigen expressed in recombinant BCG vaccines. Vaccine 2005;23:1209-24
   PubMed Web of Science ®Google Scholar
• Wang Q, Li J, Zhang X, Protective immunity of recombinant Mycobacterium bovis BCG expressing rhomboid gene against Eimeria tenella challenge. Vet Parasitol 2009;160:198-203
   PubMed Web of Science ®Google Scholar
• Aldovini A, Young RA. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccine. Nature 1992;351:479-82
   Web of Science ®Google Scholar
• Ryan AA, Nambiar JK, Wozniak TM, Antigen load governs the differential priming of CD8 T cells in response to the bacille Calmette–Guérin vaccine or Mycobacterium tuberculosis infection. J Immunol 2009;182:7172-7
   PubMed Web of Science ®Google Scholar
• Kremer L, Dupre L, Riveau G, Systemic and mucosal immune responses after intranasal administration of recombinant Mycobacterium bovis bacillus Calmette–Guerin expressing glutathione S-transferase from Schistosoma haematobium. Infect Immun 1998;66:5669-76
   PubMed Web of Science ®Google Scholar
• Walker KB, Brennan MJ, Ho MM, The second Geneva Consensus: recommendations for novel live TB vaccines. Vaccine 2010;28(11):2259-70
   PubMedGoogle Scholar
• Miyaji EN, Mazzantini RP, Dias WO, Induction of neutralizing antibodies against diphtheria toxin by priming with recombinant Mycobacterium bovis BCG expressing CRM(197), a mutant diphtheria toxin. Infect Immun 2001;69:869-74
   PubMed Web of Science ®Google Scholar
• Luo Y, Chen X, Han R, Recombinant bacille Calmette–Guerin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. Clin Exp Immunol 2001;123:264-70
   PubMed Web of Science ®Google Scholar
• Biet F, Kremer L, Wolowczuk I, Mycobacterium bovis BCG producing interleukin-18 increases antigen-specific gamma interferon production in mice. Infect Immun 2002;70:6549-57
   PubMed Web of Science ®Google Scholar
• Orme IM. Preclinical testing of new vaccines for tuberculosis: a comprehensive review. Vaccine 2006;24:2-19
   PubMed Web of Science ®Google Scholar
• Berthet F, Lagranderie M, Gounon P, Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene. Science 1998;282:759-62
   PubMed Web of Science ®Google Scholar
• Power CA,Wei G, Bretscher PA. Mycobacterial dose defines the Th1/Th2 nature of the immune response independently of whether immunization is administered by the intravenous subcutaneous or intradermal route. Infect Immun 1998;66:5743-50
   PubMed Web of Science ®Google Scholar
• Pym AS, Brodin P, Majlessi L, Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 2003;9:533-9
   PubMed Web of Science ®Google Scholar
• Grode L, Kursar M, Fensterle J, Cell-mediated immunity induced by recombinant Mycobacterium bovis Bacille Calmette–Guérin strains against an intracellular bacterial pathogen: importance of antigen secretion or membrane-targeted antigen display as lipoprotein for vaccine efficacy. J Immunol 2002;168:1869-76
   PubMed Web of Science ®Google Scholar
• Young S, O'Donnell M, Lockhart E, Manipulation of immune responses to Mycobacterium bovis by vaccination with IL-2- and IL-18-secreting recombinant Bacillus Calmette Guerin. Immunol Cell Biol 2002;80:209-15
   PubMed Web of Science ®Google Scholar
• O'Donnell MA, Aldovini A, Duda RB, Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect Immun 1994;62:2508-14
   PubMed Web of Science ®Google Scholar
• Andrade PM, Chade DC, Borra RC, The therapeutic potential of recombinant BCG expressing the antigen S1PT in the intravesical treatment of bladder cancer. Urol Oncol 2009. [Epub ahead of print]
   Web of Science ®Google Scholar
• Arnold J, de Boer EC, O'Donnell MA, Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-? J Immunother 2004;27:116-23
   PubMed Web of Science ®Google Scholar
• Old LJ, Clarke DA, Benacerraf B. Effect of Bacillus Calmette–Guerin infection on transplanted tumours in the mouse. Nature 1959;184(Suppl 5):291-2
   PubMedGoogle Scholar
• Luo Y, Yamada H, Chen X, Recombinant Mycobacterium bovis bacillus Calmette–Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. Clin Exp Immunol 2004;137:24-34
   PubMed Web of Science ®Google Scholar
• Luo Y, Yamada H, Evanoff DP, Role of Th1-stimulating cytokines in bacillus Calmette–Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells. Clin Exp Immunol 2006;146:181-8
   PubMed Web of Science ®Google Scholar
• Herr HW, Morales A. History of Bacillus Calmette–Guerin and bladder cancer: an immunotherapy success story. J Urol 2008;179:53-6
   PubMed Web of Science ®Google Scholar
• Duda RB, Yang H, Dooley DD, Recombinant BCG therapy suppresses melanoma tumor growth. Ann Surg Oncol 1995;2:542-9
   PubMed Web of Science ®Google Scholar
• Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. Clin Orthop 1991;262:3-11
   PubMedGoogle Scholar
• Nagorsen D, Marincola FM, Kaiser HE. Bacteria-related spontaneous and therapeutic remission of human malignancies. In Vivo 2002;16:551-6
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339:71-85
   PubMed Web of Science ®Google Scholar
• Wiseman CL. Inflammatory breast cancer: 10-year follow-up of a trial of surgery, chemotherapy, and allogeneic tumor cell/BCG immunotherapy. Cancer Invest 1995;13:267-71
   PubMed Web of Science ®Google Scholar
• He J, Shen D, O'Donnell MA, Induction of MUC1-specific cellular immunity by a recombinant BCG expressing human MUC1 and secreting IL2. Int J Oncol 2002;20:1305-11
   PubMed Web of Science ®Google Scholar
• Chung MA, Luo Y, O'Donnell M, Development and preclinical evaluation of a Bacillus Calmette–Guerin-MUC1-based novel breast cancer vaccine. Cancer Res 2003;63:1280-7
   PubMed Web of Science ®Google Scholar
• Yuan S, Shi C, Han W, Effective anti-tumor responses induced by recombinant Bacillus Calmette–Guérin vaccines based on different tandem repeats of MUC1 and GM-CSF. Eur J Cancer Prev 2009;18:416-23
   PubMed Web of Science ®Google Scholar
• Yuan S, Shi C, Lv Y, A novel Bacillus Calmette–Guérin-based breast cancer vaccine that co-express multiple tandem repeats of MUC1 and CD80 breaks the immune tolerance and inhibits MUC1-positive breast cancer growth. Cancer Biother Radiopharm 2009;24:607-13
   PubMed Web of Science ®Google Scholar
• Lollini PL, De Giovanni C, Pannellini T, Cancer immunoprevention. Future Oncol 2005;1:57-66
   PubMedGoogle Scholar
• Hunter CA, Reiner SL. Cytokines and T cells in host defense. Curr Opin Immunol 2000;12:413-18
   PubMed Web of Science ®Google Scholar
• Emens LA, Asquith JM, Leatherman JM, Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 2009;27:5911-18
   PubMed Web of Science ®Google Scholar